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Study design Prospective crossover study.
Animals A group of six healthy male Dunkin Hartley
guinea pigs.
Methods A single dose of meloxicam (1.5 mg kg1) was
administered orally and intravenously (IV) to six healthymale
guinea pigs. A wash-out period of 48 hours was taken into
account between administrations (oral and IV) in the same
animal. Bloodwas sampled through a central venous catheter
before administration (t¼ 0 hours) and at 0.5, 1, 2, 3, 4, 6, 8,
10, 12, 16, 20, 24 and 28 hours post administration. After
centrifugation, plasma concentrations of meloxicam were
measured by high-performance liquid chromatography with
UV detection, and pharmacokinetic parameters were calcu-
lated using noncompartmental analysis.
Results Meloxicam in guinea pigs exhibited a moderate
absorption rate after oral dosing (time to maximal plasma
concentration 3.7 ± 1.7 hours) and maximal plasma con-
centration was 0.92 ± 0.30 mg mL1. After IV adminis-
tration, total body clearance and volume of distribution
were 0.13 ± 0.04 and 0.72 ± 0.36 L kg1, respectively.
Terminal half-life was 3.7 ± 0.7 hours and 3.5 ± 1.1 hours
after IV and oral administration, respectively. Body
extraction ratio was 0.0087 and mean absorption time was
3.8 ± 1.7 hours. The absolute oral bioavailability was 0.54
± 0.14 in unfasted guinea pigs.
Conclusions and clinical relevance This study reported the
pharmacokinetics of meloxicam in guinea pigs. Studies
concerning efﬁcacy and safety are the next step towards a
rational use of this drug in guinea pigs.548meloxicam, nonsteroidal anti-inﬂammatory drug,
pharmacokinetics.
Introduction
Small mammals such as rabbits and guinea pigs are increas-
ingly kept as pets, and thus seen more often by veterinary
practitioners. In small-mammal practice, pain and inﬂamma-
tion can have far-reaching consequences as those species tend
to develop potential life-threatening complications, such as
anorexia, paralytic ileus and possible fatal dysbacteriosis.
Guinea pigs regularly suffer from infections and painful dental
conditions. Veterinarians are faced with the challenge of
relieving pain, alleviating inﬂammatory effects, and at the
same time, avoiding systemic side effects. Non-steroidal anti-
inﬂammatory drugs (NSAIDs) are commonly used in veteri-
nary practice given their distinct analgesic, antipyretic and/or
anti-inﬂammatory properties.
Meloxicam is a widely used NSAID of the oxicam group that
preferentially inhibits cyclooxygenase (COX)-2 enzyme (Türck
et al. 1996). The extent of the preference of NSAIDs for COX-2
varies between species because they express COX differently
(Brideau et al. 2001). In humans, for example, meloxicam is
from three to 77 times more speciﬁc for COX-2 compared to
COX-1 and is categorized as preferential and not speciﬁc
(Hawkey 1999). In horses and cats, data show that meloxicam
is also COX-2 selective, but at higher concentrations the
selectivity decreases (Beretta et al. 2005; Giraudel et al.
2005b). This is consistent with the observation that in hors-
es COX-1 is inhibited for a signiﬁcant amount of time when
given a higher dose of 0.6 mg kg1 IV (Lees et al. 1991).
However, due to the relative preferential inhibition of COX-2,
meloxicam is still considered to have a potent anti-
inﬂammatory effect and is better tolerated with fewer adverse
effects on the stomach mucosa and renal blood ﬂow. As a
Meloxicam in guinea pigs I Moeremans et al.result, meloxicam has a greater therapeutic range than non- or
less-selective COX inhibitors, as demonstrated in humans by
Ogino et al. (1997). The drug is registered in several countries
of the European Union, such as Belgium, for use in humans,
dogs, cats, horses, cows, and pigs (EPAR 2018).
Meloxicam has been used off label in rabbits and guinea pigs
to treat pain and inﬂammatory responses. The dose for rabbits
and guinea pigs was initially extrapolated and set at the same
dose as in cats and dogs [0.1e0.3 mg kg1 body weight (BW)],
although the recommended dose for rats and other small ro-
dents is higher, namely 1e2 mg kg1 BW (EPAR 2010).
Pharmacokinetic data in rabbits show that the extrapolated
dose might be insufﬁcient (Carpenter et al. 2009) and that
higher doses (1.0 mg kg1 for 29 days and 1.5 mg kg1 for 5
days) are safe (Turner et al. 2006; Delk et al. 2014). However,
further safety and efﬁcacy studies in rabbits are required before
conclusions can be made (Fredholm et al. 2013).
Despite the growing popularity of guinea pigs as pets, no
known conclusive studies are available on the rational use or
pharmacological properties of any NSAID in this species. In
order to obtain a better insight into an appropriate drug dosing
regimen, the aim of this study was to assess the main phar-
macokinetic parameters and absolute oral bioavailability of
meloxicam in guinea pigs.
Materials and methods
Animals and experimental protocol
The protocol was examined and approved by the ethical
committees of the Faculties of Veterinary Medicine and
Bioscience Engineering of Ghent University, Belgium
(EC2013_179). Pilot studies were performed in ﬁve animals.
Only one animal had the same features as the experimental
animals of the pharmacokinetic study, and the results from this
animal were used to gain an idea of the general pharmacoki-
netic properties of meloxicam in guinea pigs. The other four
animals were end-of-study animals previously used for regu-
latory vaccine testing, and their results were used to adapt the
dose used in the pharmacokinetic study.
The experiments, for the pharmacokinetic study, were car-
ried out in six 9-week-old healthy male guinea pigs (Cavia
porcellus) of 600e700 g BW that were previously catheterized
in the jugular vein (Charles River, France). Upon arrival,
catheters were ﬂushed and ﬁlled with a locking solution
(heparinized glucose 30%), in accordance with the instructions
of the supplier. General clinical examination showed no ab-
normalities. The animals were housed individually on wood
shavings and were allowed to adapt for 1 day. They were fed ad
libitum with commercial pelleted food (Sniff Guinea Pig, Ger-
many) and meadow hay. Drinking water was supplemented© 2019 Association of Veterinary Anaesthetists and American College of Veterina
reserved., 46, 548e555with 1 g L1 ascorbic acid. The animals were provided with a
shelter box and lived in a natural dayenight cycle, at a room
temperature of 20e22 C.
Animals were assigned to receive one of two treatments in a
random crossover design. Animals were assigned a number
based on the random opening of their transport cages prior to
the study and adaptation period. Animals 1e3 and 3e6 were
in the ﬁrst and second groups, respectively. For intravenous
administration, 1.5 mg kg1 meloxicam (Metacam 2 mg mL1
injection for cats; Boehringer Ingelheim s.a., Belgium) was
injected as a single bolus under isoﬂurane anaesthesia in the
saphenous or noncatheterized jugular vein. Anaesthesia was
induced in a box and maintained with a mask. Anaesthetic
depth was tailored, to effect, in order to facilitate the injection
and avoid unnecessary stress (pain of the injection or
restraint).
The second treatment was 1.5 mg kg1 of the oral formu-
lation (Metacam 1.5 mg mL-1 oral suspension for dogs; Boeh-
ringer Ingelheim s.a.) administered by oral gavage in the
conscious animals. After oral administration, the syringe and
gavage tube were ﬂushed with 2 mL of tap water.
There was a 48 hour washout period between the oral and
IV administration protocols. The dose and washout period
were determined based on the results of two pilot studies.
Pilot studies
A pilot study was performed to obtain full plasma pharmaco-
kinetic proﬁles in one animal (same features as the six animals
used in the crossover study). A total of 0.3 and 1 mg kg1 BW
meloxicam was administered orally with a 48 hour washout
period. The aim was to determine maximal plasma concen-
tration (Cmax) at both doses and time to maximal plasma
concentration (tmax), which was 4 hours. We also deﬁned the
appropriate blood collection protocol for the pharmacokinetic
study. After the experiment, the central venous catheter was
removed during short anaesthesia (premedication with an
intramuscular injection of buprenorphine 0.05 mg kg1, 15
minutes prior to box induction with isoﬂurane and mainte-
nance by mask). Afterwards, the animal was monitored for
signs of discomfort, food and water intake and faecal produc-
tion for 7 days. The animal received meloxicam for another 3
days (0.3 mg kg1 orally once daily). After the pharmacoki-
netic study, it was placed in a group housing with other guinea
pigs. All animals were castrated at a later time and kept in
groups with a minimum of two animals at the authors’ clinic.
They were reused for educational purposes for as long as they
were in good health. Cmax was low, so a second pilot study was
performed in four animals administered 1.5 mg kg1 BW
orally. We determined the plasma concentration at 3 and 4
hours after administration through terminal cardiac bloodry Anesthesia and Analgesia. Published by Elsevier Ltd. All rights 549
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mL sodium pentobarbital (20%, 200 mg mL1; Kela, Belgium)
was injected intracardially to kill the animals while under
general anaesthesia. Plasma concentrations were highest at 4
hours after administration and were between 1.02 ± 0.06 and
1.05 ± 0.04 mg mL1. These values were similar to Cmax/EC50
(half maximal effective concentration) values of clinically
effective doses in other species ranging between 0.8 and 1.8 mg
mL1 according to the intended effect and age (Burgos-Vargas
et al. 2004; Montoya et al. 2004; Giraudel et al. 2005a).
Pharmacokinetic study
In the pharmacokinetic study, blood samples of 0.3 mL were
taken from the central venous catheter before administration
(t ¼ 0 hour) and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24 and
28 hours post administration. The blood samples prior to drug
administration were taken to check that all meloxicam was
completely washed out prior to the next administration in the
crossover design. Plasma was separated by centrifugation
(9000  g for 5 minutes and stored at 20 C in cryotubes
(cryovials; VWR, PA, USA) until analysis. Animals were clin-
ically evaluated daily during the study. After the experiment,
the central venous catheter was removed as described for the
pilot animal. After monitoring for discomfort during 7 days,
they were placed in group housing and castrated as described
for the pilot animal. All animals were reused for educational
purposes for as long as they were in good health.
Quantification of meloxicam in plasma
Plasma concentrations of meloxicam were determined using an
in-house validated high performance liquid chromatography
(HPLC)-UVmethodbasedon themethod reportedbyBaert andDe
Backer (2002). Plasma samples were analyzed on a HPLC system
consistingof amodelP1000XRpumpwithvacuumdegassing, anPlasma protein binding ð%Þ ¼ ðtotal plasma concentration unbound plasma concentrationÞ
total plasma concentration
 100 (1)AS3000 autosampler and an UV6000LP diode array detector set
at 355 nm; all from ThermoFischer Scientiﬁc (The Netherlands).
Chromatographic separation was performed on a Hypersil GOLD
column (dp: 5 mm, 100 3mm i.d.; ThermoFischer Scientiﬁc) in
combination with a precolumn of the same type. The injection
volume was 50 mL. The mobile phase comprised of 0.1% acetic
acid in water (A) and acetonitrile (B) and a gradient elution was
performed. The ﬂow rate was 0.5 mL minute1. Samples were
prepared by pipetting 0.1 mL of plasma into a 15 mL screw-© 2019 Association of Veterinary Anaesthetists and American College550capped tube, followed by the addition of 100 mL methanol, 250
mL water, 25 mL internal standard (IS, piroxicam, 10 mg mL1 in
methanol), 150 mL 0.1 M hydrochloric acid solution and 5 mL
diethylether. Samples were extracted for 20 minutes on a hori-
zontal rotary apparatus. After centrifugation (2400  g, 5 mi-
nutes), the organic layer was transferred to a clean tube and
evaporated under nitrogen at a temperature of 40 C. The residue
was redissolved in 200 mL of the mobile phase A/B (80/20, v/v),
brieﬂy vortexed and 50 mL was injected onto the HPLC-UV
system.
Validation of the HPLC-UV method
The method was validated in-house prior to the start of the
analysis, according to a protocol described by De Baere et al.
(2011) and the following parameters were evaluated: line-
arity, within- and between-run accuracy and precision, limit of
quantiﬁcation (LOQ), limit of detection (LOD), carry-over and
speciﬁcity.
Plasma protein binding
The plasma protein binding of meloxicam in guinea pigs was
determined. Therefore, fresh blank guinea pig plasma was
spiked with meloxicam standard solution at 0.50 and 5.0 mg
mL1. One aliquot of each concentration was treated in the
same way as the pharmacokinetics trial samples (aliquot 1).
Two other aliquots (aliquot 2 and 3) were incubated for 1 hour
in a hot water bath of 38 C, and subsequently transferred onto
Microcon centrifugal ﬁlters (type Ultracel YM-30; Merck,
Belgium) and centrifuged (2980  g, 10 minutes, 41 C).
Thereafter, the obtained ﬁltrates of aliquot 2 and 3 were
treated and analyzed in the same way as the trial samples. For
quantiﬁcation, corresponding calibration curves for each
aliquot were used. The following equation was used to calcu-
late the plasma protein binding:Pharmacokinetic analysis
Plasma concentrations were modelled by noncompartmental
analysis using Phoenix 7.0 (Certara, NY, USA). Following
major pharmacokinetic parameters were calculated: Cmax,
plasma concentration after IV administration at t ¼ 0 hours
(C0), tmax, mean residence time extrapolated to inﬁnity (MRT),
area under the plasma concentrationetime curve from 0 to
time t (corresponding to the last time point with plasma con-
centrations > LOQ) (AUC 0et), area under the plasmaof Veterinary Anesthesia and Analgesia. Published by Elsevier Ltd. All rights
reserved., 46, 548e555
Figure 1 Plasma concentrations versus time proﬁle of meloxicam
(mean ± standard deviation) in six male guinea pigs after a single oral
and intravenous (IV) administration (1.5 mg kge1 body weight). At
24 hours post administration plasma levels in all animals were below
the limit of quantiﬁcation (50 ng mL1) for the IV dose.
Meloxicam in guinea pigs I Moeremans et al.concentrationetime curve from 0 to inﬁnity (AUC 0e∞)
calculated using the linear upelog down trapezoidal method,
total body clearance (Cl), volume of distribution (Vd), elimi-
nation rate constant (ke) and terminal elimination half-life (T1/
2el). F was calculated according to the following formula:
F ¼ AUC0e∞ PO/AUC0e∞ IV (2)
Body extraction ratio (E) was calculated according to the
following formula:
E¼ Cl/CO and CO ¼ cardiac output. (3)
Mean absorption time (MAT) was calculated as:
MAT ¼ MRTPO e MRTIV. (4)
Plasma concentration predictions were made towards more
frequent oral dosing (twice a day) and an increased dose (3 mg
kg1 once and twice a day), with a superposition tool in
Phoenix 7.0 (Certara). A prediction was made for each animal
and the mean value is reported in the results. The average oral
plasma concentration at steady state (Cpss) was calculated in
the various situations and animals using the following formula:
Cpss ¼ AUC0e24h /t with t ¼ dosing interval (¼ 24 hours) (5)
Statistical analysis
Descriptive values were reported as mean ± standard devia-
tion. Statistical analysis was performed with a commerciallyTable 1 Results of the in-house validation for meloxicam in guinea
diethylether and reversed phase high-performance liquid chromatograp
described by De Baere et al. (2011) and the following parameters wer
precision, limit of quantiﬁcation, limit of detection, carry-over and speci
Parameter Concentration
(ng mL¡1)
Found concentration
(ng mL¡1)
Linearity
Within-run precision and accuracy 250 231.3 ± 7.8 (n ¼ 6)
2500 2441.5 ± 220.6 (n¼ 4)
Between-run precision and
accuracy
250 247.7 ± 9.4 (n ¼ 6)
2500 2515.8 ± 52.3 (n ¼ 6)
Limit of quantiﬁcation* 50 54.0 ± 2.6 (n ¼ 4)
Limit of detectiony 14.5 ± 5.7 (n ¼ 4)
Carry-over No signal at elution zone of MEL in solv
Speciﬁcity No signal at elution zone of MEL in blan
g, goodness-of-ﬁt coefﬁcient; r, correlation coefﬁcient; RSD, relative standard deviation.
Data are presented as mean ± standard deviation.
*Limit of quantiﬁcation: lowest calibrator sample, accuracy and precision within acceptan
yLimit of detection: concentration corresponding to a signal-to-noise ratio ¼ 3:1.
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tion, MA, USA). KolmogoroveSmirnov tests were performed to
check data distribution and paired student t-tests were per-
formed to check for differences between IV and oral dosing.
Differences were considered signiﬁcant if p < 0.05.
Results
All animals remained in good general condition and showed no
adverse clinical effects during the whole trial. Animals had a
daily clinical examination by an experienced veterinarian, food
and water intake were monitored and normal during the
whole duration of the study. Faecal pellet production and
urination were normal. No obvious signs of discomfort were
recorded, and clinical parameters stayed normal throughout
the whole study.pig plasma, after liquideliquid extraction in acidic medium using
hyeUV analysis. The method was validated according to a protocol
e evaluated: linearity, within-run and between-run accuracy and
ﬁcity
Precision
(RSD %)
Accuracy
(%)
r g (%)
0.9993 ± 0.00078 (n¼ 3) 4.58 ± 2.52 (n ¼ 3)
3.4 7.5
9.0 e2.3
3.8 e0.9
2.1 0.6
4.9 8.0
ent sample
k sample
ce ranges.
ry Anesthesia and Analgesia. Published by Elsevier Ltd. All rights 551
Meloxicam in guinea pigs I Moeremans et al.The results of the analytical method validation are shown in
Table 1. The plasma concentration versus time proﬁle is dis-
played in Fig. 1. No meloxicam was detected in samples of any
animal at the time-point before the administrations.
Values of the main pharmacokinetic parameters are pre-
sented in Table 2 for both the IV and the oral treatments in the
six guinea pigs.
Overall body extraction ratio was calculated to be 0.0087, as
Peeters et al. (1980) reported total cardiac output in guinea
pigs to be 248mLminute1 kg1 and total plasma clearance in
this study was 0.13 L kg1 hour1. This assumes plasma and
blood clearance were equal.
The MAT was calculated based on the results of MRTIV and
MRTPO. MRTiv was 3.36 ±1.49 hours (range 1.0e4.1 hours)
and MRTPO equalled 7.16 ± 1.87 hours (range 5.6e10.5
hours), which resulted in a MAT of 3.81 ± 1.68 hours.
Statistical analysis showed signiﬁcant differences in AUC,
Vd, Cl (not corrected for bioavailability) and MRT between IV
and oral dosing (Table 2). A plasma protein binding of 98.4 ±
0.36% could be determined.
Based on these pharmacokinetic parameters, the plasma
concentrationetime proﬁles were predicted in four different
dosing scenarios. Calculated mean plasma concentrations at
steady state (Cpss) for the once daily oral dosing were on
average 0.28 mg mL1 for the 1.5 mg kg1 dose and 0.54 mg
mL1 for the 3 mg kg1 dose. When dosed every 12 hours,
mean Cpss were 0.54 and 1.07 mg mL
1 for 1.5 and 3 mg kg1,
respectively.
Discussion
This study reports the pharmacokinetics and oral bioavail-
ability of meloxicam in guinea pigs. There were someTable 2 Pharmacokinetic parameters of meloxicam administe
orally or intravenously (IV) in a crossover design
Pharmacokinetic parameter
AUC0e∞ (hours mg L
1)
AUC0et (hours mg L
1)
C0 (mg mL
1) (IV) or Cmax (mg mL1) (oral)
MRT (hours)
tmax (hours)
Vd (IV) (L kg
1)
Cl (IV) (L hours1 kg1)
T1/2el (hours)
kel (hours
1)
F
AUC0e∞, area under the plasma concentrationetime curve from 0 to inﬁnit
plasma concentration at injection; Cl, total body clearance; Cmax, maximal
MRT, mean residence time, tmax, time to maximal plasma concentration; T1
Data are presented as mean ± standard deviation.
*Signiﬁcant difference between IV and oral parameters (p < 0.05).
© 2019 Association of Veterinary Anaesthetists and American College552limitations to this study. We used only six animals, which
limited the power of the study; however, the crossover design
excluded some interindividual variations between the two
routes of administration. The washout period was adequate
because blood samples withdrawn prior to the next adminis-
tration conﬁrmed meloxicam was no longer detected. Addi-
tionally, the washout period (48 hours) was more than 10 
t1/2 (e.g. t1/2 ¼ 3.69 ± 0.71 hours for IV administration and
3.51 ± 1.11 hours for oral administration) (Toutain and
Bousquet-Melou 2004).
In this study, the ﬁrst blood collection for IV administration
was 30 minutes after meloxicam administration, which was
late compared to other studies. This may have inﬂuenced the
computation of AUC0e∞. However, the difference between
AUC0et and AUC0e∞, was on average only 3% (for IV
administration) and 8% (for oral administration). The differ-
ence between the measured AUC (e.g. AUC0et) and the
computed AUC0e∞ should not exceed 20%. Our results indi-
cate that the sampling points were well chosen and the esti-
mation of AUC∞ was valid (Toutain and Bousquet-Melou
2004). Another consideration was the wide interindividual
variations in pharmacokinetic parameters. This might have
been due to the inﬂuence of experimental factors. Stress for
example might have delayed gastrointestinal motility (and
absorption rate), although no clinically obvious ileus was
recorded in any animal. Only one animal showed a markedly
delayed tmax (8 hours) after oral administration compared to
the other animals (2e4 hours); the AUC was however com-
parable to the other animals.
In the present study, peak plasma concentrations after oral
dosing were higher (0.92 ± 0.30 mg mL1) compared to rabbits
that received the same dose as in our study (0.30 ± 0.09 mgred to six male guinea pigs as a single dose of 1.5 mg kg1
Administration route
IV Oral
13.76 ± 4.76* 6.44 ± 0.60*
13.38 ± 4.83* 5.94 ± 0.76*
0.98 ± 0.09 0.92 ± 0.30
3.3 ± 1.4* 7.2 ± 1.9*
3.7 ± 1.7
0.72 ± 0.36
0.13 ± 0.04
3.69 ± 0.71 3.51 ± 1.11
0.20 ± 0.03 0.23 ± 0.07
0.54 ± 0.14
y; AUC0et, area under the plasma concentration curve from 0 to t; C0,
plasma concentration; F, bioavailability; kel, elimination rate constant;
/2el, terminal half-life; Vd, volume of distribution.
of Veterinary Anesthesia and Analgesia. Published by Elsevier Ltd. All rights
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Meloxicam in guinea pigs I Moeremans et al.mL1) (Turner et al. 2006). Others reported similar peak
plasma concentrations (between 0.7 and 1.07 mg mL1) in
rabbits after receiving 1.0 mg mL1orally (Fredholm et al.
2013; Delk et al. 2014). Furthermore, the Cmax in our study
was comparable with Cmax values of therapeutic doses estab-
lished in horses and cats, namely between 1 and 2.5 mg mL1
(Toutain et al. 2004; Giraudel et al. 2005a; Raidal et al. 2013).
tmax was variable between individuals (range 2e8 hours), and
MRT after IV and oral administration was shorter than in goats
and rabbits (Toutain and Bousquet-Melou 2004; Fredholm
et al. 2013; De Vito et al. 2018). The MRT after IV adminis-
tration was shorter (3.3 hours) than after oral administration
(7.2 hours), which resulted in a MAT of 3.8 hours, which is in
agreement with our mean tmax of 3.7 hours. MAT can be
considered fairly rapid and is comparable to the MAT found
horses fasted overnight by Toutain et al. (2004).
Volume of distribution for IV administration is large (0.72 ±
0.36 L kg1) compared to the Vd of horses (0.27 L kg1),
donkeys (0.09 L kg1), swine (0.16 L kg1) and goats (0.26 L
kg1) (Sinclair et al. 2006; Pairis-Garcia et al. 2015; De Vito
et al. 2018). Plasma protein binding was 98.4%, which is
comparable to other species ranging between 96% and 98%
(EPAR 2010).
Clearance following IV administration was higher in guinea
pigs (0.13 L hour1 kg1) compared to other species [values
between 0.001 (birds) to 0.081 (horses) L hour1 kg1], but
comparable to that of donkeys (0.19 L hour1 kg1) and sheep
(0.17 L hour1 kg1) (Baert and De Backer 2002; Toutain and
Cester 2004; Sinclair et al. 2006; Stock et al. 2013). Melox-
icam is reported to be a drug with low extraction ratios in all
species. In mice, for example Chen et al. (2016) reported an
extraction ratio of 0.029. In our study, we calculated a low
overall body extraction ratio of 0.0087. Both moderate clear-
ance and volume of distribution in guinea pigs led to a rather
moderate terminal elimination half-life after oral administra-
tion (3.51 ± 1.11 hours). Similar half-lives were reported in
piglets and horses (2.5e2.7 hours) (Lees et al. 1991; Fosse
et al. 2008). Most species, however, have longer elimination
half-life values compared to guinea pigs. In rabbits, the elimi-
nation half-life after oral administration is between 6 and 9
hours. No data in guinea pigs have been published yet, but it is
important to note that juvenile animals were used in the
current study. In horses and humans, it was demonstrated that
clearance of meloxicam was more rapid in juvenile individuals
(Burgos-Vargas et al. 2004; Raidal et al. 2013). Another
consideration is the fact that all animals were male. Sex-
speciﬁc differences in plasma concentrations of meloxicam
have been noted in rats and dogs. Female rats demonstrated a
slower elimination. Meloxicam is cleared by biotransformation
in the liver through cytochrome P450 2C isoenzymes. CYP450
2C11 isoenzyme is absent in female rats, which might explain
the slower elimination (Busch et al. 1998).© 2019 Association of Veterinary Anaesthetists and American College of Veterina
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which is low compared to other herbivorous species such as
horses (98%), goats (79%), llamas (76%) and sheep (72%)
(Toutain et al. 2004; Ingvast-Larsson et al. 2011; Kreuder
et al. 2012; Stock et al. 2013). Several experimental factors
can inﬂuence the bioavailability, for example, the feeding
protocol or pharmaceutical formulation. Animals in this study
were not fasted prior to gavage. As it was the goal to mimic
clinical settings, animals were fed ad libitum meadow hay,
pelleted food and had permanent access to water. For several
NSAIDs, absorption is delayed when given orally due to
binding to hay and/or ingesta. In horses, bioavailability of
meloxicam was not signiﬁcantly inﬂuenced by the availability
of food; however, the absorption was signiﬁcantly slower in
the presence of food (Toutain et al. 2004). The low oral
bioavailability might limit the use of the oral formulation of
meloxicam in guinea pigs and other routes of administration
might be more appropriate, but this was not the scope of this
study. In this study, plasma concentrationetime proﬁles were
also predicted using a different dose (1.5 and 3 mg kg1) and
dosing interval (once or twice a day). In rats, the effective dose
to treat postoperative pain is determined at 1e2 mg kg1 BW
(Bourque et al. 2010) and in rabbits an oral dose of 1.5 mg
kg1 BW was shown to be safe if given for 5 consecutive days
(Turner et al. 2006). Therefore, a dose of 1.5 mg kg1 was
presumed to be safe in guinea pigs and this dose was hy-
pothesized to be necessary to reach therapeutic concentra-
tions in guinea pigs.
Unfortunately, no EC50 values or clinical efﬁcacy data have
been published in guinea pigs. Reported EC50 values for
meloxicam in other species are: 0.78e1.3 mg mL1 in cat and
0.13e0.73 mg mL1 in the horse, depending on the desired
effect (Toutain and Cester 2004; Giraudel et al. 2005a). Based
on these data, a dose of 1.5 mg kg1 twice a day could be
advised in guinea pigs (Cpss 0.54 mg mL
1 and Cmax 0.84 mg
mL1) (Fig. 2). Another method to estimate effective doses is to
calculate mean effective concentration (MEC) values based on
the advised dose (or dose used in a study) and the clearance in
that same study. Compared to the MEC values calculated by
other authors (horses 0.735 mg mL1, dogs 0.833 mg mL1
and cats 0.347 mg mL1), this dosing schedule (1.5 mg kg1
twice a day administered orally) would be insufﬁcient based on
the dog and horse data (Montoya et al. 2004; Toutain et al.
2004; Lehr et al. 2010).
If one calculates the time above this MEC value, the differ-
ence is even more clear. In comparison to cats, this dose would
be sufﬁcient as the time above the MEC would be on average
between 17.5 and 18 hours, compared to between 5 and 6
hours for the horse MEC.
If one would consider dosing 3 mg kg1 orally once a day to
guinea pigs the same Cpss is reached, however caution is
warranted because Cmax would reach 1.42 mg mL
1 and inry Anesthesia and Analgesia. Published by Elsevier Ltd. All rights 553
Figure 2 Predicted plasma concentrationetime proﬁle of meloxicam (mg mL1) after oral administration of 1.5 mg kg1 body weight twice daily
for 5 days. The solid line represents the calculated mean effective concentration (MEC) in horses, 0.735 mg mL1 (Toutain et al. 2004); the square
dotted line represents the MEC in dogs, 0.833 mg mL1 (Montoya et al. 2004); and the dashed line represents the MEC in cats, 0.347 mg mL1
(Lehr et al. 2010).
Meloxicam in guinea pigs I Moeremans et al.horses this concentration would cause COX-1 inhibition
related toxicity (Beretta et al. 2005).
Furthermore, predictions should always be interpreted with
caution as showed in cats. Lehr et al. (2010) concluded, based
on simulations, that a dose of 0.05 mg kg1 once daily would
not be enough to reach the EC50 values described by Giraudel
et al. 2005a. However, in cats that same dose has clinical
proven efﬁcacy (EPAR 2010; EPAR 2018). This clearly shows
the need for efﬁcacy studies besides safety and pharmacokinetic
data or simulations.
In rabbits, a dosing of 1 mg kg1 for 29 days was proven to
be safe but no data are available concerning possible accu-
mulation and safety in guinea pigs. However, in view of the
short half-life no accumulation is expected with a once daily
regimen. Further research on the safety of multiple dosing of
meloxicam, that is, on guinea pig gastrointestinal mucosa and
renal and hepatic function, is necessary. Furthermore, no real
pain scoring system is established in guinea pigs and pain
scoring might be very difﬁcult compared to other species due to
the stoic nature of this species (Ellen et al. 2016; Gleeson et al.
2016).
Conclusion
Despite the high dose of meloxicam used in this study, we
showed moderate absorption and elimination in guinea pigs.
Together with the prediction data, it should be considered that
dosing schedules might be very different in guinea pigs
compared to other species. More research on repeated dosing,
pharmacodynamics, accumulation and safety is needed to
develop appropriate dosing schedules in guinea pigs.
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